期刊文献+

淋巴细胞绝对计数对多发性骨髓瘤患者的生存影响 被引量:1

Effect of Absolute Lymphocyte Count on Survival of Multiple Myeloma Patients
下载PDF
导出
摘要 目的探讨淋巴细胞绝对计数对多发性骨髓瘤患者的生存影响。方法回顾性研究多发性骨髓瘤患者60例,查阅并记录患者的相关指标,根据患者的ALC平均数将患者分为ALC较高组和ALC较低组,分析ALC对多发性骨髓瘤患者的生存影响。结果 ALC较高组患者的年龄和β2-MG含量明显低于ALC较低组(P<0.05),而ALC较高组患者LDH、OS和有效率明显高于ALC较低组(P<0.05);2组患者在性别、ALB、D-S分期、ISS分期方面无统计学差异(P>0.05)。结论 ALC高的患者疗效和OS较好,推测ALC可能是多发性骨髓瘤患者生存的独立因素之一。 Objective To explore the effect of absolute lymphocyte count on survival of multiple myeloma patients . Methods 60 cases of primary myeloma patients were retrospectively analyzed ,related indexes were checked and record .Accord-ing to the average number of patient ’s ALC,the patients were divided into high ALC group and low ALC group ,and the effect of ALC on survival of patients with multiple myeloma was analyzed .Results Age and β2-MG of the high ALC group were lower than those of the low ALC group(P〈0.05).The LDH,OS and effective rates of patients in the high ALC group were significantly higher than those of the low ALC group;there were no statistically significant differences between the 2 groups in gender ,ALB,D-S stage,and ISS.Conclusion Patients with higher ALC has better efficacy and OS which suggests that ALC may be one of the independent factors affecting multiple myeloma patient ’s survival.
作者 韦金华
出处 《实用癌症杂志》 2014年第5期516-518,共3页 The Practical Journal of Cancer
关键词 淋巴细胞绝对计数 多发性骨髓瘤 生存 Absolute lymphocyte count Multiple myeloma Survival
  • 相关文献

参考文献8

二级参考文献107

  • 1陈灏珠,主编.实用内科学[M]第12版.北京:人民卫生出版社,2005.1 231-1 245.
  • 2Provencio M,Espana P,Millán I,et al.Prognostic factors in Hodgkin's disease.Leuk Lymphoma,2004,45(6):1133-1139.
  • 3Oki Y,Yamamoto K,Kato H,et al.Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.Eur J Haematol,2008,81(6):448-453.
  • 4Siddiqui M,Ristow K,Markovic SN,et al.Absolute lymphocyte count predicts overall survival in follicular lymphomas.Br J Haematol,2006,134(6):596-601.
  • 5Huang JJ,Jiang WQ,Lin TY,et al.Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma,nasal type.Ann Oncol,2011,22(1):149-155.
  • 6Ege H,Gertz MA,Markovic SN,et al.Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma:a retrospective study.Br J Haematol,2008,141(6):792-798.
  • 7Sehn LH,Berry B,Chhanabhai M,et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.Blood,2007,109 (5):1857-1861.
  • 8Cox MC,Nofroni I,Ruco L,et al.Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.Leuk Lymphoma,2008,49(9):1745-1751.
  • 9Plonquet A,Haioun C,Jais JP,et al.Peripheral blood natural killer cell count is associated with clinical outcome in patients with aalPI 2-3 diffuse large B-cell lymphoma.Ann Oncol,2007,18(7):1209-1215.
  • 10Street SE,Hayakawa Y,Zhan Y,et al.Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.J Exp Med,2004,199 (6):879-884.

共引文献15

同被引文献18

  • 1Weinstock M, Aljawai Y, Morgan EA, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation[J]. Br J Haematol, 2015, 169(6):851-858.
  • 2Bladé J, de Larrea CF, Rosi?ol L. Extramedullary involvement in multiple myeloma[J]. Haematologica, 2012, 97(11):1618-1619.
  • 3Wang F, Liu ZY, Xia YY, et al. Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer[J]. Oncol Lett, 2015, 10(6):3411-3418.
  • 4Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer:a systematic review and meta-analysis[J]. Ann Surg Oncol, 2016, 23(2):646-654.
  • 5International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders:a report of the International Myeloma Working Group[J]. Br J Haematol, 2003, 121(5):749-757.
  • 6Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant[J]. Br J Haematol, 1998, 102(5):1115-1123.
  • 7Ma J, Liu S, Wang Y. MicroRNA-21 and multiple myeloma:small molecule and big function[J]. Med Oncol, 2014, 31(8):94.
  • 8Spicka I. Advances in multiple myeloma therapy during two past decades[J]. Comput Struct Biotechnol J, 2014, 10(16):38-40.
  • 9Chang H, Bartlett ES, Patterson B, et al. The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system[J]. Br J Haematol, 2005, 129(4):539-541.
  • 10Bladé J, Fernández de Larrea C, Rosi?ol L, et al. Soft-tissue plasmacytomas in multiple myeloma:incidence, mechanisms of extramedullary spread, and treatment approach[J]. J Clin Oncol, 2011, 29(28):3805-3812.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部